Adaptimmune Therapeutics PLC (ADAPY) vs Seres Therapeutics, Inc. (MCRB)
- Adaptimmune Therapeutics PLC ADAPY 0.03 0.00%
- Seres Therapeutics, Inc. MCRB 1.40 −0.71%
Adaptimmune Therapeutics PLC and Seres Therapeutics, Inc. are both Biotechnology companies. Adaptimmune Therapeutics PLC and Seres Therapeutics, Inc. are of similar size ($14.6M and $14.4M). Adaptimmune Therapeutics PLC grew revenue faster over the last twelve months: −54.0% against −98.3%. Adaptimmune Therapeutics PLC has the higher net margin (−262.5% vs −2,209.6%) and the higher return on invested capital (0.00% vs −1,267.8%). Across the 17 metrics below, Adaptimmune Therapeutics PLC leads on 12 and Seres Therapeutics, Inc. on 5.
Valuation
Profitability
| Metric | ADAPY | MCRB | Biotechnology median |
|---|---|---|---|
| Gross margin | 94.81% | 100.00% | 67.24% |
| Operating margin | (427.75%) | (3,656.89%) | 0.00% |
| Net margin | (262.46%) | (2,209.55%) | 0.00% |
| Free cash flow margin | (294.49%) | (2,997.74%) | 0.00% |
| Return on equity | (1,349.52%) | (144.35%) | (50.28%) |
| Return on assets | 0.00% | (44.85%) | (45.89%) |
| Return on invested capital | 0.00% | (1,267.77%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack